Fresh analysis reveals that patients who discontinue popular GLP-1 drugs like Wegovy and Mounjaro tend to recover shed pounds at a significantly accelerated pace than those who stop conventional lifestyle programs.
Research printed in a major medical journal demonstrates that while overweight people frequently drop a large proportion of their total mass while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month once they quit.
"Individuals buying such medications need to be cognizant of the risk of rapid rebound weight gain when the therapy ends," warns researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment mass in about 18 months.
Comparing Approaches
The research, which looked at 37 of studies involving over 9,000 of patients, compared the results of these new drugs with older methods.
The team point out that individuals who lose weight through lifestyle changes alone typically have a slower creep back—around 0.1 kg a month—post-intervention.
Understanding the Fast Rebound
Experts believe the mode of action of the jabs accounts for the amplified weight return.
These medications imitate a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Long-term administration of the hormone levels several times higher than normal could lead to the body to produce less of its endogenous GLP-1, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication means hunger is uncontrolled, making binge eating a significant risk."
An Ongoing Condition?
Medical guidelines advise the injections for people with weight-linked health risks, accompanied by recommended lifestyle changes.
A number of clinicians say that, given the significant potential of weight regain, the therapy should be considered long-term.
This opinion is echoed by pharmaceutical companies, who say that the findings "highlight the long-term character of obesity," similar to managing conditions like hypertension.
User Experiences
Users who have discontinued the medication explain a powerful resurgence of cravings.
"It felt as if something flipping and I was suddenly extremely hungry," recalled a patient.
This challenge is exacerbated if individuals have not adopted permanent lifestyle or habit modifications during therapy.
Widespread Use
Recent estimates indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Adoption is higher among females than males.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Finally, experts stress that while the jabs are effective agents for weight loss, they are not a magic cure and lasting health benefits hinges on integrated lifestyle support.
